ELCC 2016 media alert: Don’t miss out!
Geneva, Switzerland – 13 April – 16 April 2016 – Around 2,000 delegates from across Europe and worldwide will learn about the latest practice-changing science in the field of thoracic oncology at the sixth European Lung Cancer Conference (ELCC) in Geneva, Switzerland, from 13-16 April 2016.
Key themes at this year's meeting include some of the most topical and keenly anticipated subjects pertinent not only to lung cancer but to oncology as a whole – such as the latest advances in immunotherapy, screening and reimbursement, new steps in the treatment of molecularly defined NSCLC and the new WHO classifications.
Organised by ESMO and the IASLC, along with partner societies ESTRO, ESTS and ETOP, this conference brings together some of the most important organisations representing thoracic oncology specialists. Having grown year-on-year, ELCC is today considered to be the point of reference in the field of lung cancer in Europe, providing a truly groundbreaking multidisciplinary programme.
You are invited to join the leading thoracic oncologists from Europe and around the world as they gather for state-of-the-art education and the latest advances in lung cancer treatment at this unique event.
- Be the first to hear late breaking results on the third generation drug osimertinib, which is indicated for patients with a T790M mutation who have progressed on an EGFR tyrosine kinase inhibitor and is now being tested as first-line therapy.
- Promising findings will be presented on the combination of immunotherapy and chemotherapy in patients with the aggressive disease mesothelioma.
- A new analysis from the SQUIRE trial in stage IV squamous non-small cell lung cancer patients with EGFR expressing tumours will be presented for the first time.
- And don't miss the news on the value of blood samples instead of tissue biopsies to test for genetic mutations so that therapies can be targeted to patients who will benefit..
- Screening (and reimbursement issues)
- Stereotactic RadioTherapy and minimally invasive local treatments
- New steps in the treatment of molecularly defined NSCLC
- The new WHO classification
- The IASLC new staging system
The full conference program is available at http://www.esmo.org/Conferences/ELCC-2016-Lung-Cancer/Programme
"Meet the Experts" – Round Table
Thursday, 14 April at 13:15 – 14:00 (CEST) – ROOM L
Don't miss the opportunity to meet leading experts commenting on the hottest thoracic oncology studies and available to answer your questions.
In order to better manage the round table, we kindly ask you to confirm your interest by filling in the following form: http://esmo.formstack.com/forms/elcc2016_meet_the_experts_roundtable
Registration is free to bona fide journalists on presentation of a letter of assignment and a valid press card.
Media representatives are required to observe and abide by the ELCC Media Policy.
To register for the event, please fill out the Complimentary Media Registration Form
Media registration in advance is strongly recommended although on-site registration will still be possible.
Registered journalists can access all conference sessions and the ELCC Press Room.
Press Room opening hours
Wednesday, 13 April 2016 11:00 – 18:00
Thursday, 14 April 2016 08:00 – 18:00
Friday, 15 April 2016 08:00 – 18:00
Saturday, 16 April 2016 08:00 – 13:00
- Abstracts accepted for presentation and for publication in the ELCC 2016 Abstract Book will be published online on the ELCC 2016 Web site on Wednesday, 06 April 2016 12:00 (CEST)
- Abstracts selected for the official ELCC 2016 Press Programme (suffix _PR) will be made public at the beginning of the official session during which they're presented
Journalists are required to observe embargoes as indicated, thank you!
For further information please contact:
ELCC Press Office
E-mail: [email protected]
Office tel: +41 (0)91 973 19 04
About the European Lung Cancer Conference (ELCC)
The European Lung Cancer Conference (ELCC) has become the reference event in Europe for professionals treating lung cancers. From surgical resection to complex treatment options with novel agents and novel targets; from lung cancer in non-smokers to issues surrounding gender; from various forms of lung cancer, the big killer, to rare forms of chest tumors: the third edition of the ELCC will provide a comprehensive multidisciplinary overview of the latest as well as of the state-of-the-art knowledge in thoracic malignancies, covering different aspects such as prevention, screening, diagnosis, treatment modalities and the results of basic, clinical and translational research, presented by top international academic experts. More than 1,500 attendees are expected from throughout Europe and the rest of the world.
About the European Society for Medical Oncology (ESMO)
ESMO is the leading professional organisation for medical oncology. With more than 13,000 members representing oncology professionals from over 130 countries, ESMO is the society of reference for oncology education and information. We are committed to supporting our members to develop and advance in a fast-evolving professional environment.
ESMO's educational resources support an integrated, multi-professional approach to cancer care. We have European roots and a global reach: we welcome oncology professionals from around the world and we seek to erase boundaries in cancer care as we pursue our mission across oncology, worldwide. http://www.esmo.org
About the International Association for the Study of Lung Cancer (IASLC)
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated to the study of lung cancer. Founded in 1974, the association's membership includes more than 3,500 lung cancer specialists in 80 countries. To learn more about IASLC please visit http://www.iaslc.org.
ESMO Press Office